2018-03-23T08:52:50-07:00 2017-06-30 990 2016-07-01 251462312 MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION MAGE 4126418957 3339 Ward Street Pittsburgh PA 15213 Michael Annichine CEO 4126418949 2018-03-22 128.147.28.1 2016 2021-01-29 14:40:06Z Michael Annichine 3339 Ward Street Pittsburgh PA 15213 83186632 0 X www.mageewomens.org X 1984 PA Magee-Womens Research Institute (MWRI), the first and largest research institute in the U.S. devoted exclusively to women's health, is a recognized leader conducting unprecedented research and advancing clinical knowledge in many areas affecting women, including: reproductive biology, breast cancer, ovarian cancer, genomics and personalized therapies, HIV immunization and prevention, fertility preservation, and pelvic floor research. Magee-Womens Research Institute is dedicated to the transformation of health research for the good of all humankind . 25 22 0 250 0 0 48885965 52281257 373199 348044 1917924 2530221 734444 733243 51911532 55892765 28738678 28028462 0 0 14208909 14728965 0 0 868265 13113335 14333063 56060922 57090490 -4149390 -1197725 92483980 93147030 47958056 46310891 44525924 46836139 X The Board approved mission of MWRIF is to advance scientific knowledge in the fields of reproductive biology and medicine; translate this knowledge into improved health for women and infants; train current and future scholars of reproductive sciences; and foster community investment and involvement in women's health. 0 0 51548092 28028462 1212659 See Schedule O 0 0 0 51548092 1 1 0 0 0 0 0 0 0 1 1 1 0 0 1 0 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 46 0 0 0 0 0 0 0 1 1 0 0 0 0 X 25 22 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CO CT DC FL GA HI KS KY MA MD MI MN MO MS NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV X Lisa Ascencio Director of Finance 4126418957 3339 Ward Street Pittsburgh PA 15213 Theresa Bone Director 1 0 X 0 0 0 Stephen Emery Director 1 0 X 0 0 0 Leslie Davis Director 1 0 X 0 0 0 Robert Edwards Director 2 0 X 0 0 0 Joan Ellenbogen Director 1 0 X 0 0 0 Laura Ellsworth Director 1 0 X 0 0 0 Margaret Joy Director 1 0 X 0 0 0 Karen Kelley Director 1 0 X 0 0 0 Joan Snyder Kuhl Director 1 0 X 0 0 0 Ed Lettieri Director 1 0 X 0 0 0 Arthur Levine Director 1 0 X 0 0 0 Susan McGalla Secretary 1 0 X 0 0 0 Linda S Melada Director 1 0 X 0 0 0 William Pietragallo Director 1 0 X 0 0 0 K Scott Roy Vice Chair 2.5 0 X X 0 0 0 W Scott Sanford Director 1 0 X 0 0 0 Patricia Siger Director 1 0 X 0 0 0 David Spigelmyer Director 1 0 X 0 0 0 Jason Harrison Treasurer 2.5 0 X X 0 0 0 Peggy Snavely Director 1 0 X 0 0 0 Carrie Coghill Chair 4 0 X X 0 0 0 Kelly R Gray Vice Chair 2.5 0 X X 0 0 0 Michael Annichine CEO 40 0 X X 244628 0 11747 Yoel Sadovsky Executive Director/Professor 92 0 X X 561339 0 68039 Arthur Scully III Vice President 40 X X 195674 0 39688 Gerald Schatten Professor 40 X 306442 0 52258 Sharon Hillier Professor 40 X 304608 0 45175 Ian McGowan Professor 40 X 264586 0 47836 Aleksander Rajkovic Professor 40 X 186342 0 34645 Kyle Orwig Professor 40 X 241406 0 31802 2305025 0 331190 42 0 1 1 Pricewaterhouse Coopers LLC PO BOX 7247-8001 Philadelphia PA 19170 Consulting Services 316250 Routes2Results 8 Bowman Meadow Wallington UK SM67DN Research Services 250813 Garrison Hughes Inc 100 First Avenue Suite 200 Pittsburgh PA 15222 Consulting Services 150529 Paraxel International One Kilmainham Square Inchicore Rad Dublin EI Research Services 130815 Pursuant Group Inc Post Box 203421 Dallas TX 75320 Consulting Services 129500 9 X 67900 0 236257 0 42952941 9024159 435634 52281257 Service Fee Revenue 541380 336118 336118 0 0 Student Intern Program Stipend Recovery 541712 11926 11926 0 0 0 0 0 0 348044 850782 0 0 850782 0 0 0 0 0 0 0 0 864615 0 0 0 864615 0 864615 864615 0 0 28719286 0 27039847 0 1679439 0 1679439 0 0 1679439 122648 236257 254020 -131372 0 -131372 0 55892765 1212659 0 2398849 18788860 18788860 9239602 9239602 863761 43176 820585 0 11021173 8793409 1912776 314988 2844031 2250003 503741 90287 4626 4626 69340 69340 180569 180569 1320698 459446 564500 296752 9880 2175 680 7025 526361 266126 109569 150666 176717 44987 99314 32416 2910564 2659407 249520 1637 1214240 1059191 66544 88505 526906 521731 5175 1928791 1864931 63215 645 Laboratory Equipment & Maintenance 426840 426840 0 0 Medical Research Lab Supplies 2654220 2654220 0 0 Various Lab Testing and Processing Charges 1314468 1314468 0 0 Fundraising Expense included in Part VIII -254020 0 0 -254020 1322863 1159520 29154 134189 57090490 51548092 4674133 868265 1677336 3662706 9932504 8475073 177992 150740 0 0 0 0 0 0 0 0 558497 538704 51091274 20156984 32569590 30934290 0 0 47568061 49385517 0 0 0 0 0 0 92483980 93147030 4673719 3079628 3807261 3777341 10074670 10843301 0 0 0 0 0 0 29358117 28536360 0 0 44289 74261 47958056 46310891 X 7678556 7377165 18680712 19704095 18166656 19754879 44525924 46836139 92483980 93147030 -1197725 3507940 0 0 0 0 X 0 1 X 1 1 1 X 50556469 45725654 58771737 48885965 52281257 256221082 0 0 0 0 0 0 50556469 45725654 58771737 48885965 52281257 256221082 9416727 246804355 1976447 1719011 1597092 1783852 1715397 8791799 0 0 0 0 0 0 265012881 2436257 0.93129 0.92226 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 20147000 62258 2494863 0 719827 0 21984294 22878830 873005 -58413 0 3546422 0 20147000 22336456 860738 316392 0 634756 0 22878830 20383708 11625 2506831 0 565708 0 22336456 18959728 56904 1897654 0 530578 0 20383708 0.093 0.899 0.008 1 0 0 0 0 0 44437642 14496444 29941198 0 931198 746000 185198 0 5722434 4914540 807894 0 0 0 0 30934290 0 0 Money Market 5354301 F Fixed Income Securities 11070378 F Domestic Equity 19435463 F International Equity 9330320 F Alternative Investments 3214101 F Beneficial Interest in Trust 980954 F 49385517 0 Agency Funds held for Womens Auxillary 74261 74261 59814714 3507940 340558 0 0 3848498 55966216 180569 -254020 -73451 55892765 57504499 340558 0 0 0 340558 57163941 180569 -254020 -73451 57090490 Schedule D, Part V, Line 4 Endowments are used to carry out the mission of the organization, i.e., to conduct medical research related to women's health and to support the operations of Magee Womens Hospital. Schedule D, Part XI, Line 4b Fund Raising Expenses netted with fund raising revenue in Part VIII, Line 8b Schedule D, Part XII, Line 4b Fund raising expenses of $254,020 reported as expense in audited financial statements but reported as a revenue offset in Part VIII Line 8(b) of 990. 1 Europe (including Iceland and Greenland) 0 0 Grantmaking Bio-medical Research 339783 Sub-Saharan Africa 0 0 Grantmaking Bio-medical Research: Clinical trials of microbicides for the prevention of HIV 8729443 North America (including Canada and Mexico, but not the United States) 0 0 Grantmaking Bio-medical Research: Recovery after general anesthesia with Ultiva vs Hypnotic B 170376 0 0 9239602 Sub-Saharan Africa To support collaborative bio-medical research 488809 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research 737733 Wire Transfer 0 Europe (including Iceland and Greenland) To support collaborative bio-medical research. 87138 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research. 17916 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research. 1159789 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research. 3238881 Wire Transfer 0 Europe (including Iceland and Greenland) To support collaborative bio-medical research. 211355 Wire Transfer 0 North America (including Canada and Mexico, but not the United States) To support collaborative bio-medical research. 170376 Wire Transfer 0 Europe (including Iceland and Greenland) To support collaborative bio-medical research. 41290 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research. 1946877 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research. 723772 Wire Transfer 0 Sub-Saharan Africa To support collaborative bio-medical research. 415577 Wire Transfer 0 11 1 1 0 0 0 0 0 Schedule F, Part I, Line 2 Schedule F, Part I, Line 2: All Grants and assistance to foreign organizations relate to collaborative bio-medical research with the Organization. Each arrangement is formalized with a contract which includes specific terms and conditions that must be met. Recipients are required to submit a detailed accounting of all expenditure incurred under the contract. This is reviewed for contract compliance and appropriateness and only then cash is remitted to them as reimbursement. Each recipient organization is also required to submit annual reports of all research activities funded by the grant, together with the results of the research. This information is reviewed by the U.S. scientist leading the research. Savor Pittsburgh 230313 137925 92388 0 0 20825 15778 1500 145345 Fly Fishing 45100 23850 21250 0 0 15000 591 0 1850 6 78814 69804 9010 0 0 4814 11601 0 5353 354227 231579 122648 0 0 40639 27970 1500 152548 222657 -100009 1 Carnegie Mellon University PO Box 371032 Pittsburgh PA 15250 250969449 501(c)(3) 439530 0 Bio-medical Research Case Western University 10900 Euclid Avenue Cleveland OH 44106 341018992 501(c)(3) 80819 0 Bio-medical Research Columbia University 116th St and Broadway New York NY 10027 135598093 501(c)(3) 59127 0 Bio-medical Research Duke University 1525 West WT Harris Blvd- 2C2 Charlotte NC 28262 560532129 501(c)(3) 292175 0 Bio-medical Research Eastern VA Medical School 700 W Olney Rd Norfolk VA 23507 546055378 501(c)(3) 10572 0 Bio-medical Research Yeshiva University 1300 Morris Park Avenue Bronx NY 10461 237075620 501(c)(3) 59038 0 Bio-medical Research Family Health International 359 Blackwell Street Durham NC 27701 237413005 501(c)(3) 1403073 0 Bio-medical Research Fred Hutchinson Cancer Research Center 1100 Fairview Avenue N Seattle WA 98109 237156071 501(c)(3) 56538 0 Bio-medical Research The Hektoen Institute of Medical Research 2240 West Ogden Ave FL 2 Chicago IL 60612 362244897 501(c)(3) 15609 0 Bio-medical Research Johns Hopkins University 733 North Broadway Baltimore MD 21218 520595110 501(c)(3) 848993 0 Bio-medical Research Massachusetts Institute of Technology 77 Massachusetts Avenue Cambridge MA 02319 042103594 501(c)(3) 51294 0 Bio-medical Research New York University 70 Washington Square South New York NY 10012 135562308 501(c)(3) 149135 0 Bio-medical Research The Pennsylvania State University 408 Old Main University Park PA 16801 246000376 115 14083 0 Bio-medical Research Population Council One Dag Hammarskjold Plaza New York NY 10017 131687001 501(c)(3) 267411 0 Bio-medical Research Public Health Foundation Enterprises 12801 Crossroads Pkwy S City of Industry CA 91746 952557063 501(c)(3) 64773 0 Bio-medical Research Regents of the University of Michigan 500 S State St Ann Harbor MI 48109 386006309 501(c)(3) 23326 0 Bio-medical Research Research Foundation for Mental Hygiene 150 Broadway Menands NY 12204 141410842 501(c)(3) 258049 0 Bio-medical Research Research Triangle Institute 5265 Capital Boulevard Raleigh NC 27616 560686338 501(c)(3) 876325 0 Bio-medical Research San Francisco Dept of Public Health 1380 Howard Street San Francisco CA 94103 000000000 115 37724 0 Bio-medical Research Research Fdn for the State University of New York PO Box 9 Albany NY 12201 141368361 501(c)(3) 176260 0 Bio-medical Research Tulane University 800 East Commerce Road Harahan LA 70123 740423889 501(c)(3) 22412 0 Bio-medical Research University of Texas One UTSA Circle San Antonio TX 78249 746000089 501(c)(3) 485446 0 Bio-medical Research Regents of the University of California at Davis One Shields Avenue Davis CA 95616 946036494 501(c)(3) 38340 0 Bio-medical Resarch University of Alabama at Birmingham 1720 Second Avenue South Birmingham AL 35294 636005396 501(c)(3) 287245 0 Bio-medical Research University of California at San Diego 9500 Gilman Avenue La Jolla CA 92093 956006144 501(c)(3) 611078 0 Bio-medical Research Regents of the University of Colorado 1775 Aurora Court Denver CO 80045 846000555 115 473515 0 Bio-medical Research University of North Carolina at Chapel Hill 104 Airport Dr Chappel Hill NC 27599 566001393 501(c)(3) 468319 0 Bio-medical Research University of Pennsylvania PO Box 785541 Philadelphia PA 19178 231352685 501(c)(3) 94273 0 Bio-medical Research The University of Tennessee 201 Andy Holt Tower Knoxville TN 37996 626001634 115 9080 0 Bio-medical Research University of Utah 201 S Presendents Circle Salt Lake UT 84112 000000000 501(c)(3) 7156 0 Bio-medical Research University of Washington Gerberding Hall G80 Seattle WA 98195 916001537 115 382261 0 Bio-medical Research The Board of Regents of University of Nebraska 985045 Nebraska Medical Center Omaha NE 68198 470049123 501(c)(3) 9469 0 Bio-medical Research HJF Medical Research International Inc 6720 A Rockledge Dr Suite 100 Bethesda MD 20817 522322791 501(c)(3) 107907 0 Bio-medical Research University of Pittsburgh 4200 Fifth Avenue Pittsburgh PA 15260 250965591 501(c)(3) 9661709 0 Bio-medical Research Magee Womens Hospital of UPMC 300 Halket Street Pittsburgh PA 15213 250965420 501(c)(3) 648844 0 Contribution for Patient Care and other Hospital Activities 35 0 Schedule I, Part I, Line 2 Schedule I, Part I, Line 2: Each recipient of grant funding enters into a contract with MWRIF. The contract details allowable use of funds and includes budget of expenditures. Funds are released to recipients on a cost reimbursement basis. The recipient submits a report summarizing the expenses incurred which is compared by MWRIF personnel against budgets and terms of the contract before funds are released. X 1 1 X 0 0 0 0 0 0 0 1 0 Yoel Sadovsky Executive Director/Professor 448681 0 109877 0 2781 0 48670 0 19369 0 629378 0 0 0 Michael Annichine CEO 243851 0 0 0 777 0 0 0 11747 0 256375 0 0 0 Arthur Scully III Vice President 195074 0 0 0 600 0 23912 0 15776 0 235362 0 0 0 Gerald Schatten Professor 305842 0 0 0 600 0 31800 0 20458 0 358700 0 0 0 Ian McGowan Professor 213986 0 50000 0 600 0 31900 0 15936 0 312422 0 0 Sharon Hillier Professor 254008 0 50000 0 600 0 30898 0 14276 0 349782 0 0 0 Kyle Orwig Associate Professor 202640 0 38166 0 600 0 24605 0 7195 0 273206 0 0 0 Aleksander Rajkovic Assistant Professor 160090 0 25757 0 495 0 19800 0 14845 0 220987 0 0 0 Schedule J, Part I, Line 1a Membership dues for the Duquesne Club, a private club located in Pittsburgh's downtown business district, are paid by MWRIF for Arthur Scully, VP of Development. The Club's facility is used to host Board and Donor meetings and related events. Schedule J, Part I, Line 3 The CEO, Michael Annichine, joined the organization effective 04/11/2016. His initial compensation was determined by the Executive Committee of the Board and approved by the Board of Directors. He is employed by the University of Pittsburgh Medical Center, and a written employment agreement was executed to document all employment terms including compensation. The Executive Director is dually employed by both the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC). 100% of his time is spent on either his biomedical research or his Executive Director responsibilities, so MWRIF is financially responsible for his total compensation. Each of the three organizations are involved in evaluating the ED's compensation taking into account accomplishments, responsibilities, and comparison to AAMC (American Association of Medical Colleges) benchmarks. The initial salary as well as subsequent adjustments must be approved by senior management of the University and UPMC, and is also approved by select independent directors of MWRIF board. A written employment contract is used by both employers to document all employment terms including compensation. All paperwork regarding the process and approvals is maintained by the respective organizations Schedule J, Part I, Line 7 In addition to a base compensation from each employer, Dr. Sadovsky is eligible for incentive compensation as follows: From UPMC, he is eligible for performance based incentive compensation as part of his employment contract. Performance is evaluated against a list of predetermined goals and payment is made in the subsequent fiscal year. From the University of Pittsburgh, he is eligible for a research incentive based on certain criteria established by the University for all researchers. This is tied to his own research lab and is not related to his function as Executive Director of MWRIF. Gerald Schatten, Sharon Hillier, Ian McGowan, Kyle Orwig, and Aleksander Rajkovic are also eligible for the University of Pittsburgh research incentive mentioned above, if they meet the criteria established by the University. Schedule J, Part II Aleksander Rajkovic is dually employed by the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC). He divides his time between clinical work and research. The reportable wages shown on Schedule J Part II and Part VII Line 1a represent the portion of his combined salary attributable to his research work which is the responsibility of MWRIF. UPMC is responsible for the portion of his combined salary attributable to his clinical work. X 12813 Retail Value X 17 410435 FMV X Food Served at Event 8 12385 FMV 0 0 1 1 Schedule M, Part I, Line 32b Registered Stock Brokers are used to sell stock donations. Stocks are sold immediately upon receipt. Form 990, Part I, Line 5 (and Part V Line 2a): MWRIF doesn't have any employees of its own. All individuals who work in support of the mission of MWRIF are employed either by the University of Pittsburgh or the University of Pittsburgh Medical Center (UPMC). MWRIF is billed by each organization for the cost of salary and fringe benefits corresponding to the effort these individuals expend in support of the MWRIF mission. MWRIF records such costs as compensation on its financial statements. Payroll taxes are filed by the employer organizations. Form 990, Part III, Line 4a Magee-Womens Research Institute (MWRI), the first and largest research institute in the U.S. devoted exclusively to women's health, is a recognized leader conducting unprecedented research and advancing clinical knowledge in many areas affecting women, including: reproductive biology, breast cancer, ovarian cancer, genomics and personalized therapies, HIV immunization and prevention, fertility preservation, and pelvic floor research. Magee-Womens Research Institute is dedicated to the transformation of health research for the good of all humankind. Though women comprise 50% of the population, they give birth to 100% of future generations. As researchers, this fact has led us to the realization that women's health is the key to human wellness. Remarkable for its potential to revolutionize the art and science of medicine, this insight is the foundation of the Magee Movement. By embracing this new perspective, we will develop pragmatic solutions and prevent problems once considered inevitable. We envision a future in which all physicians and researchers routinely address the genetic and gestational causes of chronic and devastating developments like diabetes and cardiovascular disease in an attempt to prevent their occurrence. We believe that our best defense against infectious disease is to empower women. We are dedicated to fostering wellness by incorporating gender-based medicine. These tenets have motivated us to refocus our research in to three pillars: PILLAR 1: 9-90: From conception onward, the first nine months of pregnancy contain the key to many of life's questions about health and well-being. Through our 9-90TM research, scientists investigate how the 9 months of pregnancy impact the next 90 years of life. The nine months in utero are so universally important because the moment of greatest plasticity - or the ability to be easily shaped or molded - is during pregnancy. It is during this time that factors such as environmental exposure, nutrition, and infection, as well as other influences, most greatly impact fetal development and leave a lasting mark. Studying this "human blueprint" allows scientists to better predict the conditions that will affect a person later in life and potentially change or cure those conditions. Areas of study in 9-90 are: REPRODUCTIVE DEVELOPMENT: Uncovering the mechanisms that underlie genetic abnormalities is crucial to reducing birth defects and improving the health of infants. PREGNANCY & NEWBORNS: A healthy start in life is the key to a lifetime of well-being. Magee scientists continue to make lifesaving discoveries about key diseases such as preeclampsia, fetal growth abnormalities, preterm birth, prenatal genetics and the lifelong impact stemming from these diseases through research spanning fetal development, pregnancy and pregnancy outcomes that shape maternal and neonatal health. REPRODUCTIVE PHYSIOLOGY & FERTILITY: Infertility is heartbreaking to the couple who desperately wants a child to love. Our scientists study the fundamental mechanisms that govern germ cell biology and complex pathways that lead to human infertility, to discover means for restoring fertility to diverse populations including young cancer survivors. GENETICS: Genetic studies of placental development are furthering medical science's understanding of how hormonal, nutritional and environmental signals in the womb influence genes that regulate all aspects of our physiology. PILLAR 2: GENDER SPECIFIC MEDICINE (GSM): For hundreds of years, scientists have been studying human disease processes while employing male research subjects almost exclusively. This approach has established a baseline for understanding, but truly effective human health research demands the study of both female and male responses to disease origin, prevention, and treatment. The differences between women and men and the distinctive ways they present with disease, respond to treatment, and recover can tell us much about how to ensure each patient receives the right treatment in the right way at the right time. Areas of study in GSM are: WOMENS CANCERS: At Magee, our response to Cancer is to find new and better ways to prevent and treat it. With recent breakthroughs in genomic discovery, we now have the tools to identify biomarkers for cancer risk, severity and prognosis. Through large scale clinical trials performed as a part of the national consortia, Magee scientists and physicians investigate ovarian and other pelvic cancers, examine the causes, prevention and treatment of breast cancer, and assess the impact cancer has on a woman's quality of life. UROGYNECOLOGY: We are unyielding in our determination to find ways to improve patient care in the treatment of the female pelvic floor. We are set on finding better treatments for conditions that affect women of reproductive age through maturity. WOMENS HEALTH & WELLNESS: An appalling one in four women will experience domestic abuse in her lifetime. Specific areas of focus include intimate partner violence, teen pregnancy, prenatal care and postpartum depression. We also pinpoint gaps in the quality of health and healthcare across racial, ethnic and socioeconomic groups that result in higher incidence of chronic diseases, higher mortality and poorer health outcomes for women. PILLAR 3: INFECTIOUS DISEASES: Magee is focusing its efforts on the global threat of infectious diseases and our clinical trials are yielding breakthrough results all over the world. Our organization receives more HIV&AIDS research funding from the NIH than any other research center in the country - and, in 2006, the NIH established the Microbicide Trials Network (MTN) at Magee-Womens Research Institute. Led by Sharon Hillier, PhD, the MTN is a worldwide collaborative clinical trials network focused on preventing the transmission of HIV. Today, eleven years later, the MTN operates more than 20 sites in Africa, Southeast Asia and the United States. Form 990, Part VI, Section A, Line 2 Directors Arthur Levine and Linda Melada have a family relationship. Form 990, Part VI, Section B, Line 11b The initial draft of the Form 990, which is prepared by the Accounting Manager, is reviewed by the Director of Finance. It is then reviewed externally by representative of MWRIF's external auditors Maher Duessel. After that, the Audit Committee, a sub-committee of the Board of Directors, reviews and provides a report to the Board. A copy of the Form 990 is provided to the full Board of Directors prior to filing with the IRS Form 990, Part VI, Section B, Line 12c The organization has a conflict of interest policy that is driven by the classification of each individual as follows: Board members are required to sign a formal conflict of interest questionnaire annually prior to the beginning of each fiscal year for which they are a member. The forms are reviewed internally by the VP of Development and Communications and actual or potential conflicts are reported to the Board Chair. * Designated individuals (managers and above, and any employee holding a position of influence or trust) supporting MWRIF who are employed by UPMC are required to follow their employer mandated conflict of interest policy which includes annual electronic disclosures, as well as additional disclosures as related circumstances change. These are reviewed and monitored by the UPMC Ethics and Compliance Committee. If potential and actual conflicts are identified, a Conflict Management Plan must be developed and submitted to the Committee. Failure to disclose potential conflicts or to follow the approved conflict management plan will result in disciplinary action. * Designated individuals (all faculty, staff with administrator IV title or above and any others designated based on their responsibilities) working at MWRIF who are employees of the University of Pittsburgh are required to follow their employer mandated conflict of interest policy which includes annual electronic conflict of interest disclosures, as well as additional disclosures as related circumstances change. These are reviewed by the individual's department head and reported to University senior management as well as maintained by the Conflict of Interest Committee. Potential or actual conflicts are handled by the employees first line supervisor and a management plan developed. The plan is submitted to senior management as well as the COI committee for review. Sanctions may be applied for non-compliance with the requirements of the policy or with management plans, including a letter of reprimand, special monitoring of future work, removal from the particular project, probation, suspension, salary reduction, or initiation of steps leading to possible reduction in rank or termination of employment. Form 990, Part VI, Section B, Line 15 The CEO, Michael Annichine, joined the organization effective 04/11/2016. His compensation was determined by the Executive Committee of the Board and approved by the Board of Directors. He is employed by the University of Pittsburgh Medical Center, and a written employment contract was executed to document all employment terms including compensation. The Executive Director is dually employed by both University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC). 100% of his time is spent on either his medical research (about 46 hours/week average) or on his Executive Director responsibilities (an additional 46 hours/week average), for an average total of 92 hours per week. MWRIF is financially responsible for his total compensation and it reimburses the University of Pittsburgh and UPMC for his compensation. Each of the three organizations are involved in evaluating the ED's compensation taking into consideration his accomplishments, responsibilities, and comparing against AAMC (American Association of Medical Colleges) benchmarks. The initial salary as well as any subsequent adjustments are approved by senior management of the University and UPMC and by selected external members of the MWRIF Board. All paperwork regarding the process and approvals is maintained by the respective organizations Form 990, Part VI, Section C, Line 19 The Conflict of Interest Policy, governing documents, and financial statements are available at the Organization's business office located at 3339 Ward street, Pittsburgh, PA 15213. Form 990, Part VIII, Line 6a The research conducted at MWRIF occurs in a facility located at 204 Craft Avenue. UPMC owns this building and MWRIF is renting the space from them. Since the lease agreement with UPMC is long term (30 years), for accounting purposes it has to be recorded as a capital lease recognizing both an asset and a liability on MWRIF's books. The mortgage/note payable disclosed on Line 24 of Part X is the liability on this account. The lease agreement does not contain any terms implying that MWRIF will ever own or have the option to buy the building. The rental income disclosed in Part VIII is generated by subleases between MWRIF and several research labs that are part of the University of Pittsburgh, allowing them to occupy a portion of the space MWRIF is renting from UPMC. These particular University of Pittsburgh researchers collaborate with MWRIF researchers on a regular basis on large biomedical research projects where physical proximity facilitates the collaborative process and allows them to meet, share equipment and other resources as needed to make the collaboration more efficient and hopefully more successful. The objective in renting the space to the University of Pittsburgh is to facilitate the collaboration, not to generate profit. So the rental income disclosed in Part VIII is sublease income that offsets a portion of MWRIF's lease expense. MWRIF has no acquisition indebtedness which would require the rental income to be disclosed as unrelated business income.